204 related articles for article (PubMed ID: 31924380)
1. Janus kinase inhibitor delgocitinib suppresses pruritus and nerve elongation in an atopic dermatitis murine model.
Yamamoto Y; Otsuka A; Nakashima C; Ishida Y; Honda T; Egawa G; Amano W; Usui K; Hamada Y; Wada M; Tanimoto A; Konishi N; Hayashi M; Matsushita M; Kabashima K
J Dermatol Sci; 2020 Feb; 97(2):161-164. PubMed ID: 31924380
[No Abstract] [Full Text] [Related]
2. Small molecule drugs for the treatment of pruritus in patients with atopic dermatitis.
Soeberdt M; Kilic A; Abels C
Eur J Pharmacol; 2020 Aug; 881():173242. PubMed ID: 32504692
[TBL] [Abstract][Full Text] [Related]
3. Phase 1 studies to assess the safety, tolerability and pharmacokinetics of JTE-052 (a novel Janus kinase inhibitor) ointment in Japanese healthy volunteers and patients with atopic dermatitis.
Nakagawa H; Nemoto O; Yamada H; Nagata T; Ninomiya N
J Dermatol; 2018 Jun; 45(6):701-709. PubMed ID: 29665062
[TBL] [Abstract][Full Text] [Related]
4. Delgocitinib ointment, a topical Janus kinase inhibitor, in adult patients with moderate to severe atopic dermatitis: A phase 3, randomized, double-blind, vehicle-controlled study and an open-label, long-term extension study.
Nakagawa H; Nemoto O; Igarashi A; Saeki H; Kaino H; Nagata T
J Am Acad Dermatol; 2020 Apr; 82(4):823-831. PubMed ID: 32029304
[TBL] [Abstract][Full Text] [Related]
5. New therapies for controlling atopic itch.
Furue M; Kadono T
J Dermatol; 2015 Sep; 42(9):847-50. PubMed ID: 26332459
[TBL] [Abstract][Full Text] [Related]
6. Discovery of a Janus Kinase Inhibitor Bearing a Highly Three-Dimensional Spiro Scaffold: JTE-052 (Delgocitinib) as a New Dermatological Agent to Treat Inflammatory Skin Disorders.
Noji S; Hara Y; Miura T; Yamanaka H; Maeda K; Hori A; Yamamoto H; Obika S; Inoue M; Hase Y; Orita T; Doi S; Adachi T; Tanimoto A; Oki C; Kimoto Y; Ogawa Y; Negoro T; Hashimoto H; Shiozaki M
J Med Chem; 2020 Jul; 63(13):7163-7185. PubMed ID: 32511913
[TBL] [Abstract][Full Text] [Related]
7. Topical E6005, a novel phosphodiesterase 4 inhibitor, attenuates spontaneous itch-related responses in mice with chronic atopy-like dermatitis.
Andoh T; Yoshida T; Kuraishi Y
Exp Dermatol; 2014 May; 23(5):359-61. PubMed ID: 24645735
[TBL] [Abstract][Full Text] [Related]
8. Antipruritic Effects of Janus Kinase Inhibitor Tofacitinib in a Mouse Model of Psoriasis.
Hashimoto T; Sakai K; Sanders KM; Yosipovitch G; Akiyama T
Acta Derm Venereol; 2019 Mar; 99(3):298-303. PubMed ID: 30460374
[TBL] [Abstract][Full Text] [Related]
9. A randomized, double-blind, vehicle-controlled crossover study to determine the anti-pruritic efficacy, safety and local dermal tolerability of a topical formulation (srd174 cream) of the long-acting opiod antagonist nalmefene in subjects with atopic dermatitis.
Herzog JL; Solomon JA; Draelos Z; Fleischer A; Stough D; Wolf DI; Abramovits W; Werschler W; Green E; Duffy M; Rothaul A; Tansley R
J Drugs Dermatol; 2011 Aug; 10(8):853-60. PubMed ID: 21818506
[TBL] [Abstract][Full Text] [Related]
10. PAR2 Mediates Itch via TRPV3 Signaling in Keratinocytes.
Zhao J; Munanairi A; Liu XY; Zhang J; Hu L; Hu M; Bu D; Liu L; Xie Z; Kim BS; Yang Y; Chen ZF
J Invest Dermatol; 2020 Aug; 140(8):1524-1532. PubMed ID: 32004565
[TBL] [Abstract][Full Text] [Related]
11. Case report of atopic dermatitis with refractory pruritus markedly improved with the novel use of clonidine and trimeprazine.
Genois A; Haig M; Des Roches A; Sirard A; Le May S; McCuaig CC
Pediatr Dermatol; 2014; 31(1):76-9. PubMed ID: 22747704
[TBL] [Abstract][Full Text] [Related]
12. Long-term safety and efficacy of delgocitinib ointment, a topical Janus kinase inhibitor, in adult patients with atopic dermatitis.
Nakagawa H; Nemoto O; Igarashi A; Saeki H; Murata R; Kaino H; Nagata T
J Dermatol; 2020 Feb; 47(2):114-120. PubMed ID: 31820485
[TBL] [Abstract][Full Text] [Related]
13. Immunomodulating Agents as Antipruritics.
Erickson S; Nahmias Z; Rosman IS; Kim BS
Dermatol Clin; 2018 Jul; 36(3):325-334. PubMed ID: 29929604
[TBL] [Abstract][Full Text] [Related]
14. Possible Antipruritic Mechanism of Cyclosporine A in Atopic Dermatitis.
Ko KC; Tominaga M; Kamata Y; Umehara Y; Matsuda H; Takahashi N; Kina K; Ogawa M; Ogawa H; Takamori K
Acta Derm Venereol; 2016 Jun; 96(5):624-9. PubMed ID: 26671728
[TBL] [Abstract][Full Text] [Related]
15. Antihistamines for atopic dermatitis.
Phillips RL; Koenig CJ
J Fam Pract; 2000 Mar; 49(3):267. PubMed ID: 10735488
[No Abstract] [Full Text] [Related]
16. Neurotropin suppresses itch-related behavior in NC/Nga mice with atopic dermatitis-like symptoms.
Kamo A; Tominaga M; Matsuda H; Kina K; Kamata Y; Umehara Y; Ogawa H; Takamori K
J Dermatol Sci; 2016 Mar; 81(3):212-5. PubMed ID: 26725918
[No Abstract] [Full Text] [Related]
17. Delgocitinib: First Approval.
Dhillon S
Drugs; 2020 Apr; 80(6):609-615. PubMed ID: 32166597
[TBL] [Abstract][Full Text] [Related]
18. Spontaneous scratching behaviour in DS-Nh mice as a possible model for pruritus in atopic dermatitis.
Yoshioka T; Hikita I; Asakawa M; Hirasawa T; Deguchi M; Matsutani T; Oku H; Horikawa T; Arimura A
Immunology; 2006 Jul; 118(3):293-301. PubMed ID: 16827890
[TBL] [Abstract][Full Text] [Related]
19. Effects of TS-022, a newly developed prostanoid DP1 receptor agonist, on experimental pruritus, cutaneous barrier disruptions and atopic dermatitis in mice.
Arai I; Takaoka A; Hashimoto Y; Honma Y; Koizumi C; Futaki N; Sugimoto M; Takahashi N; Inoue T; Nakanishi Y; Sakurai T; Tanami T; Yagi M; Ono N; Nakaike S
Eur J Pharmacol; 2007 Feb; 556(1-3):207-14. PubMed ID: 17141215
[TBL] [Abstract][Full Text] [Related]
20. Echinacea purpurea-derived alkylamides exhibit potent anti-inflammatory effects and alleviate clinical symptoms of atopic eczema.
Oláh A; Szabó-Papp J; Soeberdt M; Knie U; Dähnhardt-Pfeiffer S; Abels C; Bíró T
J Dermatol Sci; 2017 Oct; 88(1):67-77. PubMed ID: 28610718
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
